A Comprehensive Review of Nanoparticles in Breast Cancer Treatment: Mechanisms, Applications, and Clinical Translation
DOI:
https://doi.org/10.33687/ricosbiol.03.09.76Keywords:
Breast Cancer, Nanomedicine, Nanoparticles, Targeted Drug Delivery, Theranostics, Liposomes, Polymeric Nanoparticles, Multidrug ResistanceAbstract
Breast cancer remains the most commonly diagnosed malignancy among women worldwide, with significant heterogeneity in molecular subtypes and treatment responses. While conventional therapies like chemotherapy, radiation, and surgery have improved outcomes, they often suffer from limitations including systemic toxicity, drug resistance, and poor biodistribution. The emergence of nanotechnology has revolutionized cancer therapeutics by enabling targeted drug delivery, enhanced imaging, and combinatorial treatment approaches. This review provides a comprehensive overview of nanoparticle applications in breast cancer management, with a particular focus on their mechanisms of action, specific applications across different breast cancer subtypes, and the current state of clinical translation. We detail the unique physicochemical properties of various nanoplatforms—including liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles—that enable passive and active targeting through the Enhanced Permeability and Retention (EPR) effect and surface functionalization with targeting ligands. The review expands on the use of nanoparticles for conventional chemotherapeutic delivery, gene therapy, immunotherapy, and theranostic applications. Finally, we discuss challenges in clinical translation and future perspectives for personalized nanomedicine in breast cancer treatment.
Downloads
References
Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 160 (2), 117-134.
Basho, R. K., and Gilcrease, M. Z. (2022). Targeting triple-negative breast cancer with nanomedicine. Cancer Treatment Reviews, 104 , 102340.
Blanco, E., Shen, H., and Ferrari, M. (2021). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33 (9), 941-951.
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M. P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., Moreno, V., Li, R. K., Tiangco, B., Herraez, A. C., Gronchi, A., Mangel, L., Sy-Ortin, T., Hohenberger, P., de Baère, T., ... Le Péchoux, C. (2019). NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. The Lancet Oncology, 20 (8), 1148-1159.
Borchard, G., Amiji, M., Anderson, W., Andresen, T. L., Aseyev, V., Barreto, J. A., Bawa, R., Berkowitz, S. A., Bhandari, P., Bogs, T., Ceña, V., Chen, C., Dandekar, P., Duncan, R., Ekladious, I., Espelin, C. W., Farokhzad, O. C., Foldvari, M., Furtado, D., ... Zhang, J. (2022). The safety of nanomedicines: navigating the complex regulatory landscape. Advanced Drug Delivery Reviews, 181 , 114079.
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., and Préat, V. (2012). PLGA-based nanoparticles: an overview of biomedical applications. Journal of Controlled Release, 161 (2), 505-522.
Dreaden, E. C., Austin, L. A., Mackey, M. A., and El-Sayed, M. A. (2012). Size matters: gold nanoparticles in targeted cancer drug delivery. Therapeutic Delivery, 3 (4), 457-478.
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., and McCullough, J. (2013). The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine, 9 (1), 1-14.
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., and O'Shaughnessy, J. (2021). nab-Paclitaxel for the treatment of metastatic breast cancer: a comprehensive review. Expert Review of Anticancer Therapy, 21 (7), 735-748.
Grodzinski, P., Kircher, M. F., Goldberg, M., and Gabizon, A. (2023). Integrating nanotechnology with immunotherapy for breast cancer treatment. Nature Reviews Clinical Oncology, 20 (5), 299-315.
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., and Barry, S. T. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 108 , 25-38.
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J. J., Song, Y. H., Summa, J., ... Zale, S. (2019). Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science Translational Medicine, 11 (475), eaau5959.
Khan, D. R., Rehman, S., Muhammad, K., Qazi, F., Odeh, L., Waseem, M., and Khan, M. I. (2022). EGFR-targeted nanotherapeutics for triple-negative breast cancer. Biomaterials, 280 , 121273.
Maeda, H., Nakamura, H., and Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced Drug Delivery Reviews, 65 (1), 71-79.
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, M., and Scomparin, A. (2023). Nanotechnology-based approaches to overcome resistance in HER2-positive breast cancer. Advanced Drug Delivery Reviews, 191 , 114542.
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., and Schmid, P. (2016). Phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2-positive metastatic breast cancer. Journal of Clinical Oncology, 34 (15_suppl), 1017-1017.
Mintzer, M. A., and Grinstaff, M. W. (2011). Biomedical applications of dendrimers: a tutorial. Chemical Society Reviews, 40 (1), 173-190.
Müller, R. H., Shegokar, R., and Keck, C. M. (2020). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cosmetic and dermal applications. International Journal of Pharmaceutics, 591 , 119994.
Pal, S., Mohanta, K., Donato, L., Tekade, M., and Tekade, R. K. (2021). Nanoparticle-mediated delivery of endocrine therapies for breast cancer treatment. Molecular Pharmaceutics, 18 (3), 909-923.
Shi, J., Kantoff, P. W., Wooster, R., and Farokhzad, O. C. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nature Reviews Cancer, 17 (1), 20-37.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71 (3), 209-249.
Sutton, D., Nasongkla, N., Blanco, E., and Gao, J. (2021). HER2-targeted nanoparticles for breast cancer therapy. Pharmaceutical Research, 38 (2), 255-267.
Veiseh, O., Gunn, J. W., and Zhang, M. (2010). Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Advanced Drug Delivery Reviews, 62 (3), 284-304.
Wang, X., Zhang, Y., Li, Z., Zhao, W., Chen, L., and Liu, Y. (2024). Combination nanotherapy for metastatic breast cancer treatment. Nature Nanotechnology, 19 (1), 45-58.
Wei, X., Wang, Y., Zhang, J., Wang, H., Zhang, L., Li, P., and Zhao, Y. (2023). Stimuli-responsive nanoparticles for controlled drug delivery in breast cancer therapy. Advanced Materials, 35 (12), 2206845.
Weiss, G. J., Waypa, J., Blaydorn, L., Coats, J., McGahey, K., Sangal, A., Niu, J., Lynch, C. A., Faridi, M. H., Mahadevan, D., and Miller, K. J. (2020). Phase II trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology, 38 (6_suppl), 612-612.
Published
Data Availability Statement
Ricos Biology Journal
Issue
Section
Categories
License
Copyright (c) 2025 Abouelhag H. A.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
